Evidence map›Paper›PMID 41922384›Full record

ArticleNature communications2026

TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation.

Bruno Ghirotto, Luís Eduardo Gonçalves, Vivien Ruder, Christina James, Elizaveta Gerasimova, Tania Rizo, Holger Wend, Michaela Farrell, Juan Atilio Gerez, Natalia Cecilia Prymaczok and 15 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Bruno GhirottoDepartment of Stem Cell Biology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-6835-3329
Luís Eduardo GonçalvesDepartment of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Vivien RuderDepartment of Stem Cell Biology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0009-0000-8203-2943
Christina JamesDepartment of Stem Cell Biology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-7443-929X
Elizaveta GerasimovaDental Clinic 1-Department of Operative Dentistry and Periodontology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Tania RizoDepartment of Stem Cell Biology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Holger WendDepartment of Stem Cell Biology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Michaela FarrellDepartment of Stem Cell Biology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Juan Atilio GerezInstitute of Molecular Physical Sciences, ETH Zürich, Zürich, Switzerland.ORCID 0000-0002-3326-2897
Natalia Cecilia PrymaczokInstitute of Molecular Physical Sciences, ETH Zürich, Zürich, Switzerland.
Merel KuijsInstitute of Computational Biology, Helmholtz Center, Munich, Germany.ORCID 0000-0003-4193-1138
Maiia ShulmanInstitute of Computational Biology, Helmholtz Center, Munich, Germany.
Anne HartebrodtBiomedical Network Science Lab, Department Artificial Intelligence in Biomedical Engineering (AIBE), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Iryna ProtsDental Clinic 1-Department of Operative Dentistry and Periodontology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-9561-0909
Arne GessnerInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-1729-4231
Michael ViethInstitute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Klinikum Bayreuth, Bayreuth, Germany.
Friederike ZunkeDepartment of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-0408-6388
Jürgen WinklerDepartment of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0003-0630-9204
David B BlumenthalBiomedical Network Science Lab, Department Artificial Intelligence in Biomedical Engineering (AIBE), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-8651-750X
Fabian J TheisInstitute of Computational Biology, Helmholtz Center, Munich, Germany.
Roland RiekInstitute of Molecular Physical Sciences, ETH Zürich, Zürich, Switzerland.ORCID 0000-0002-6333-066X
Claudia GüntherDepartment of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Markus NeurathDepartment of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0003-4344-1474
Pooja Gupta *Department of Stem Cell Biology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0009-0009-3328-5157
Beate Winner *Department of Stem Cell Biology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. beate.winner@fau.de.ORCID 0000-0002-6909-0564

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 031L0309ADeutsche Forschungsgemeinschaft (German Research Foundation) 505539112Deutsche Forschungsgemeinschaft (German Research Foundation) INST 90/1048-1 FUGG
6 · The paper itself

Abstract

Gastrointestinal dysfunction often precedes motor symptoms in Parkinson's disease (PD), suggesting the enteric nervous system (ENS) is central to early pathogenesis. How α-synuclein contributes to ENS dysfunction, and how inflammation modulates this, remains unclear. Here we show that Tumor Necrosis Factor alpha enhances α-synuclein accumulation in induced pluripotent stem cell-derived enteric neurons and glia, and impairs the malate-aspartate shuttle, a key pathway for mitochondrial energy production. This drives a metabolic shift toward glutamine oxidation in patient cells. This metabolic impairment reduces overall mitochondrial function, which is partially rescued by the neuroprotective compound Chicago-Sky-Blue 6B. Furthermore, transcriptomic and histological analyses of human gut tissue from inflammatory bowel disease patients reveal that inflammation-associated metabolic suppression and α-synuclein upregulation occur beyond PD, representing general hallmarks of intestinal inflammation. These findings highlight a conserved metabolic vulnerability in the ENS and establish patient-derived enteric lineages as a robust platform to model inflammatory ENS pathology.

Indexed as

Aspartic AcidEnteric Nervous SystemInflammatory Bowel DiseasesMalatesParkinson DiseaseTumor Necrosis Factor-alphaalpha-SynucleinAnimalsFemaleHumansInduced Pluripotent Stem CellsInflammationIntestinesMaleMiceMitochondriaalpha-SynucleinAspartic Acidmalic acidTumor Necrosis Factor-alpha

Identifiers

PMID41922384
PMCPMC13057073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.